ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • General Endocrinology

    Caruntu C, Boda D, Constantin C, Caruntu A, Neagu M

    Catecholamines Increase in Vitro Proliferation of Murine B16F10 Melanoma Cells

    Acta Endo (Buc) 2014 10(4): 545-558 doi: 10.4183/aeb.2014.545

    Abstract
    Context. Melanoma is the most aggressive skin cancer, with significant morbidity and mortality, and one factor that may influence the course of disease is stress. Objective. Our aim was to evaluate the effect of corticosterone, norepinephrine, epinephrine on murine B16F10 melanoma cells in vitro proliferation. Methods. B16F10 melanoma cells were treated with different concentrations of tested hormones. The proliferative capacity of melanoma cells was quantified by MTS assay and the cell viability was quantified as membrane integrity evaluation measured by lactate dehydrogenase (LDH) release. Results. B16F10 cells treated with corticosterone showed no significant changes. In contrast, norepinephrine exposure stimulated the cell proliferation (P = 0.0003). Treatment with 1 μM norepinephrine induced the highest increase in cell proliferation (OD 492 = 0.27 ± 0.02) statistically significant to both control (OD 492 = 0.17 ± 0.01; p = 0.0003), 10 nM norepinephrine (OD 492 = 0.16 ± 0.00; p = 0.0004) and 100 nM norepinephrine (OD 492 = 0.19 ± 0.01; p = 0.002). Likewise, treatment with epinephrine increased cell proliferation (p = 0.0004). Exposure to 5 μm epinephrine induced a stimulation of cell proliferation (OD 492 = 0.28 ± 0.02) significantly higher compared to controls (OD 492 = 0.17 ± 0.01; p = 0.0004), 50 nM epinephrine (OD 492 = 0.17 ± 0.00; p = 0.001) and 500 nM epinephrine (OD 492 = 0.173 ± 0.00; p = 0.001). Conclusions. Our results may open new perspectives concerning the link between stress hormones and melanoma, emphasizing a direct stimulating in vitro effect induced by catecholamines on melanoma B16F10 cells proliferation.
  • Case Report

    Celik O, Buyuktas D, Acbay O

    Alternate Days Treatment with Teriparatide in Postsurgical Hypoparathyroidism

    Acta Endo (Buc) 2011 7(4): 545-550 doi: 10.4183/aeb.2011.545

    Abstract
    The conventional treatment of hypoparathyroidism consists of vitamin D analogues in combination with oral calcium\r\nsupplementation. This treatment modalities induce chronic hypercalciuria which leads to nephrocalcinosis, nephrolithiasis and renal insufficiency. Here we report the case of a 32-year-old woman who developed hypocalcemia and hypercalciuria under treatment with high doses of vitamin D\r\nanalogs and oral calcium. She had cerebral calcification, nephrocalcinosis under this treatment. Stable calcium levels were achieved with synthetic human parathyroid hormone treatment that was given in alternate days. PTH appears to be an alternative and effective treatment in hypoparathyroidism.
  • Letter to the Editor

    Koracevic G, Zdravkovic M

    What is Stress Hyperglycemia? A Suggestion for an Improvement of its Definition

    Acta Endo (Buc) 2021 17(4): 548-551 doi: 10.4183/aeb.2021.548

    Abstract
    Context. Stress hyperglycemia has been studied in numerous critical illnesses for several decades. Despite the extensive accumulation of knowledge about this topic, the definition of stress hyperglycemia is not updated since 2007. Subjects and Methods. We performed a narrative review about stress hyperglycemia in acute myocardial infarction (AMI), aiming to improve its current definition and to give evidence supporting this. Results. The definition of stress hyperglycemia in 2021 we recommend is: “SH is a high ABGly in an AMI patient irrespective of DM status. It can be calculated as e.g., “stress hyperglycemia ratio” or “admission glucose delta”/“glycemic gap”. This definition may serve to start a consensus document of the experts in the field. The evidence accumulates supporting the possibility to recognize stress hyperglycemia also in AMI patients with diabetes mellitus (DM) by calculating glycemia during the previous 2-3 months using glycated hemoglobin. Moreover, it is now obvious that 2007 definition of stress hyperglycemia did not take into account the necessity to separate cut-offs for the subgroups with vs. without DM. Conclusions. We demonstrated the insufficiency of the current 2007 definition of stress hyperglycemia, provided evidence-based recommendation for the improvement and suggested the need for a consensus of the experts on this topic. In order to optimize the treatment of stress hyperglycemia in numerous critical illnesses, we ought to have its universal definition (as we already have the universal definition of AMI).
  • Book Review

    Badiu C

    Evidence-Based Endocrinology 4th Edition

    Acta Endo (Buc) 2019 15(4): 549-549 doi: 10.4183/aeb.2019.549

  • Case Series

    Capatina C, Vintila M, Gherlan I, Dumitrascu A, Caragheorgheopol A, Procopiuc C, Ciubotaru V, Poiana C

    Craniopharyngioma - Clinical And Therapeutic Outcome Data in a Mixed Cohort of Adult and Paediatric Cases

    Acta Endo (Buc) 2018 14(4): 549-555 doi: 10.4183/aeb.2018.549

    Abstract
    Background. Craniopharyngiomas are benign but locally invasive tumours of the sellar region that arise from ectopic embryonic remnants of Rathke's pouch, affecting both children (adamantinomatous type -aCP) and adults (papillary type -pCP) and associated with significant morbidity. Objective. To study the clinical presentation of CRF as well as the posttreatment evolution of craniopharyngioma in children versus adults in a large mixed cohort. Material and methods. We performed a retrospective review of CRF patients evaluated in the National Institute of Endocrinology in Bucharest between 1990 and 2016. Results. A total of 107 patients (72 adults, 35 children) with a mean follow-up of 6.2 years were included. The presenting symptoms were mostly headache, visual impairment, symptoms of hypopituitarism, diabetes insipidus. Some symptoms or hormonal abnormalities were significantly more prevalent in the children group (p<0.05): nausea/ vomiting (47.8% vs 16.7%), photophobia (21.7% vs 5.6%), diabetes insipidus(28.5% vs 8.3%), GH deficiency (68.8% vs 17.1%). Impaired visual acuity (67.6%of cases) or visual fields (71.4%) were more frequent in adults compared to children (44.1%; 51.6%). The tumor dimensions were similar in both groups (3.05± 1.05 cm in children; 2.7± 1.07 cm in adults). Massive suprasellar extension reaching the third ventricle was frequently present in all cases. All cases underwent surgery but only a minority of those not cured received postoperative adjuvant radiotherapy. Frequent postoperative complications were: aggravation of the endocrine deficit (>80% of cases in both groups needed chronic replacement therapy), central diabetes insipidus (68.2% children, 34.3% of adults). Conclusions. Despite similar tumor dimensions and extension compared to adults, craniopharyngioma in children is more frequently associated with signs of intracranial pressure. The results and complications of treatment are similar in adults and children
  • Case Report

    Cristea C, Plaiasu V, Ochiana D, Draghicenoiu Neagu R, Gherlan I, Mardarescu M

    Sexual Ambiguity Associated with "in utero" Antiretroviral Exposure

    Acta Endo (Buc) 2011 7(4): 551-560 doi: 10.4183/aeb.2011.551

    Abstract
    Mixed gonadal dysgenesis and ovotesticular disorders of sex development, are rare conditions that occur sporadically,\r\nwith unknown prevalence. Clinical manifestation of this diseases is sexual ambiguity. The authors present a pediatric\r\ncase with sexual ambiguity and karyotype 45, X/46, XY, the child of a HIV-positive mother receiving multiple antiretroviral treatments for a period of 16 years.
  • Endocrine Care

    Macarie AE, Vesa SC, Pasca L, Donca V

    Predictor Role of N-Terminal Pro-Brain Natriuretic Peptide for Mortality in Elderly Patients with Heart Failure

    Acta Endo (Buc) 2013 9(4): 551-563 doi: 10.4183/aeb.2013.551

    Abstract
    Background. Heart failure (HF) is a disease with a high prevalence in the elderly population. Problems posed by HF diagnosis and management within this special category validate the interest in studying ways to improve the quality and duration of life in these patients. Aim. To determine the prognostic accuracy of certain clinical and laboratory parameters and to predict mortality rates in elderly patients with HF. Study design. It is a cohort, analytical, prospective, observational, crosssectional study conducted between 2006- 2008. Data regarding patient survival over a period of six months were recorded from the moment of enrollment. Subjects and methods. The study group consisted of 177 patients of over 65 years of age admitted to geriatrics, internal medicine and cardiology units, diagnosed with HF. A series of clinical and laboratory data from these patients has been examined, including NT-proBNP and CRP. Results. CRP levels higher than 3.57 mg/dL determined a hazard ratio (HR) of 3.9 (CI95% 1 - 15.2, p=0.04), urea levels higher than 79 mg/dL determined a HR of 8.8 (CI95% 1.1 - 37.4, p=0.003) and NT-proBNP levels higher than 9370 pg/mL determined a HR of 18.6 (CI95% 5.2 - 66.2, p<0.001). After multiple comparison adjustments (Bonferroni correction), only urea and NT-proBNP remained independent variables predicting 6-month mortality in elderly patients with HF. Conclusion. High NT-proBNP and urea levels were independent predictors for mortality in elderly patients with heart failure.
  • General Endocrinology

    Emandi AC, Gafencu M, Pienar C

    Impact of increased body mass on growth patterns in school children

    Acta Endo (Buc) 2012 8(4): 551-563 doi: 10.4183/aeb.2012.551

    Abstract
    The increase in prevalence of obesity in children is well known worldwide, with important implications for health.\r\nAim. To evaluate the growth patterns of normal weight, overweight, obese and underweight schoolchildren from western Romania, in order to understand how body mass is related to height gain.\r\nMaterial and method. A total of 3626 children aged 7-18 years, were examinated, between February 2010-June 2011. Children were classified as normal weight, underweight, overweight and obese, using IOTF criteria.\r\nResults. We present the growth curves in regard to BMI class and the comparison of the 50th percentile of each BMI class, in boys and girls separately. The period of significant height difference/year at the 50th percentile for each BMI class indicates that overweight and obese boys have important height gain between 11-14 years, while for underweight boys it is constant between 11-18 years. In overweight and obese girls, an important height difference/year is observed between 7-11 years, while in underweight group it is seen between 10-13 years.\r\nConclusions. In boys, increased BMI leads to taller young stature, delayed growth spurt, but similar height at age of 18 years, while in the underweight group we observed a prolonged growth spurt with increased height at 18 years. Increased BMI, in girls, resulted in early growth spurt and similar height at 18 years when compared to normal weight peers. Final height was independent of BMI in both girls and boys.
  • Images in Endocrinology

    Yu J, Qin C, Huang S, Ye X, Meng N

    Treatment of Giant Juvenile Breast Fibroadenoma by Single Hole Breast Endoscopy: a Case Report

    Acta Endo (Buc) 2021 17(4): 552-553 doi: 10.4183/aeb.2021.552

  • Notes & Comments

    Uyaroglu OA

    An Interesting Experience with Empagliflozin: Unidentified Body Odor

    Acta Endo (Buc) 2021 17(4): 554-556 doi: 10.4183/aeb.2021.554

    Abstract
    Context. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) are a new class of oral antidiabetic drugs. Objective. Side effects of drugs are frequently encountered with increasing use in clinical practice. Design/Subjects and Methods. We present a case with an unidentified body odor that has not been described yet in the literature as an adverse effect of SGLT2-I. Results. A 49-year-old female patient with Type 2 DM was applied to our clinic for routine control. She had been receiving sitagliptin/metformin 50/1000 mg b.i.d. Her fasting plasma glucose was 160 mg/dL and HbA1c was 8%. Empagliflozin 10 mg/day was added to therapy. The patient noticed that two weeks after starting empagliflozin treatment, she began to smell herself and felt a bad/foul odor was released from her body. The patient associated these complaints with the new drug(empagliflozin) stopped two weeks ago. She also stated that all these complaints had disappeared one week after stopping the medication and there were no complaints at the moment. Conclusions. Here we report an unidentified body odor as a potential empagliflozin-associated adverse event. There was a close temporal relationship between empagliflozin intake and the development and the occurrence of the described odor.